

*Program*

# **Regulatory Sciences for Biologics and Vaccines: Accelerating Development and Enabling Manufacturing Innovation**

April 23-26, 2017

Lansdowne Resort  
Leesburg, VA, USA

## **Conference Co-Chairs**

**Prof. Antonio Moreira**  
University of Maryland, Baltimore County, USA

**Dr. David Robinson**  
Robinson Vaccines and Biologics LLC, USA



**Engineering Conferences International**

32 Broadway, Suite 314  
New York, NY 10004, USA

Phone: 1-212-514-6760

[www.engconfintl.org](http://www.engconfintl.org) – [info@engconfintl.org](mailto:info@engconfintl.org)

**Lansdowne Resort**  
**44050 Woodridge Parkway**  
**Leesburg, Virginia 20176**  
**Tel: 1-703-729-8400**

Engineering Conferences International (ECI) is a not-for-profit global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

#### ECI BOARD MEMBERS

Barry C. Buckland, President  
Mike Betenbaugh  
Nick Clesceri  
Peter Gray  
Michael King  
Raymond McCabe  
David Robinson  
Eugene Schaefer  
P. Somasundaran

Chair of ECI Conferences Committee: Nick Clesceri

ECI Technical Liaison for this conference: Beth Junker

ECI Executive Director: Barbara K. Hickernell

ECI Associate Director: Kevin M. Korpics

## **ORGANIZING COMMITTEE**

Wolfgang Berthold/bbphc GmbH (Germany)

Arindam Bose/AbiologicsB, LLC

Gabriele Dallman/Biopharma Excellence (Germany)

Wei-Shou Hu/University of Minnesota

Beth Junker/Bioprocess Advantage

Lynne Krummen/Genentech

Tony Lubiniecki/Janssen Pharmaceuticals R&D, LLC

Jose Menezes/Instituto Superior Tecnico (Portugal)

Tony Mire-Sluis/AstraZeneca

Todd Ranheim/Takeda

Thomas Ryll/Immunogen

Sangeetha Sagar/Sanofi

Gene Schaefer/Janssen Pharmaceuticals

Ken Surowitz/Dr. Reddy's

TG Venkateshwaran/Merck

Weichang Zhou/WuXi Biologics (China)

**Conference Sponsors**

**Amgen**

**Bill & Melinda Gates Foundation**

**Merck and Co. Inc.**

**Pfizer**

## **Sunday, April 23, 2017**

16:00 – 17:15	Conference Check-in
17:30 – 18:30	Dinner
18:30 – 19:00	Opening comments
19:00 – 20:00	<b>Keynote Speaker 1 – Harnessing Science and Technology to Accelerate High Impact Drug Discovery</b> Dr. Ron dePinho, CEO, MD Anderson Cancer Center
20:00 – 21:00	<b>Keynote Speaker 2 – Opportunities to Improve Global Human Health</b> Katey Owen, Director, The Bill & Melinda Gates Foundation
21:00 – 22:00	Social hour

### ***NOTES***

- Locations for the technical and poster sessions will be announced on site.
- All meals will be in the Riverside Hearth Restaurant.
- Audiotaping, videotaping and photography of presentations are prohibited.
- Speakers – Please leave at least 5 minutes for questions and discussion.
- Speakers – Please ensure your talk adheres to your given time allotment. Talks that go over their allotment reduce time for valuable discussion and can disrupt the conference program.
- Turn your cellular telephones to vibrate or off during technical sessions.
- After the conference, ECI will send an updated participant list to all participants. Please check your listing now and if it needs updating, you may correct it at any time by logging into your ECI account.
- Please do not smoke at any conference functions.
- Please write your name in the front of this program booklet so it can be returned if misplaced.

## **Monday, April 24, 2017**

- 07:30 – 08:30 Breakfast
- 08:30 – 12:00 **Oral Session 1 – Vaccines – Rapid Responses to Global Health Challenges**  
Chair: Vijay Yabannavar, Vice President, Technical Operations Merck & Co Inc/MSD
- 08:40 – 09:30 Plenary Lecture – Rapid response to the Ebola crisis  
Jayanthi Wolf, Director Global Regulatory Affairs, Merck & Co Inc/MSD
- 09:30 – 10:00 Facilitation of a rapid response by self-amplifying mRNA vaccines  
Jeffrey B. Ulmer, GSK Vaccines
- 10:00 – 10:30 Coffee break (*Sponsored by Pfizer*)
- 10:30 – 11:00 Platforms prepare manufacturing for rapid responses,  
Jeffrey Welch, Emergent Biosolutions
- 11:00 – 11:30 Rapid vaccine responses to emerging pathogens using a platform technology  
Tim Hahn, Novavax
- 11:30 – 12:00 Rapid response to pandemic influenza using a licensed recombinant seasonal influenza vaccine platform  
Penny Post, Protein Sciences
- 12:00 – 13:00 Lunch
- 13:00 – 15:20 **Oral Session 2 – Managing Products in a Complex Environment**  
Chair: Stefanie Pluschkell, Executive Director, Pfizer
- 13:00 – 13:50 Plenary Lecture: Title TBA  
Jeff Baker, FDA
- 13:50 – 14:20 Innovation and continuous improvement in a seemingly accelerated regulatory environment  
Roger Nosal, Pfizer Inc
- 14:20 – 14:50 Managing CMC for global accelerated marketing approvals  
Pradip Ghosh-Dastidar, BMS, presenting on behalf of IFPMA
- 14:50 – 15:20 PATH - A global health nonprofit organization in support of international vaccine manufacturing  
George Robertson, PATH
- 15:20 – 16:00 Coffee break
- 16:00 – 18:00 **Workshops**  
Workshop 1 – National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)  
(Chairs: Barry Buckland, Stacy Springs and Louise Johnson, NIIMBL)  
Workshop 2 – Managing Complexity  
(Chairs: Steffi Pluschkell, Pfizer, and Kumar Namdev, Sanofi)
- 18:00 – 19:00 Dinner

**Monday, April 24, 2017 (continued)**

- 19:00 – 21:00      **Oral Session 3 – Accelerating Development**  
Chair: Tony Mire-Sluis, Head of Global Quality, AstraZeneca
- 19:10 – 20:00      Plenary Lecture – Leveraging knowledge to accelerate the development of biological products  
Tony Mire Sluis, Head of Global Quality, Astra Zeneca
- 20:00 – 20:30      Accelerating strategies for FIH process development  
Margaret Ricci, Amgen
- 20:30 – 21:00      Systems analysis and design for accelerating process and cell line development  
Wei-Shou Hu, University of Minnesota
- 21:00 – 21:15      **Rapid Fire Oral Presentations/Poster Session Preview**  
Chair: Sevda Deldari, UMBC
- 21:15 – 22:15      **Poster Session 1 / Social Hour**



**Tuesday, April 25, 2017**

- 07:30 – 08:30 Breakfast
- 08:30 – 12:00 **Oral Session 4 – Approaches to innovative and streamlined manufacturing**,  
Chair: Aine Hanly, VP Drug Substance Technologies & Site Head Amgen Cambridge
- 08:40 – 09:30 Plenary Lecture – Accelerating development and managing risk  
Tony Lubiniecki, Senior Fellow, Janssen Pharmaceuticals R&D
- 09:30 – 10:00 Managing and Mitigating Risk in Biologics Process Transfer  
Charles Goochee, Janssen Pharmaceuticals
- 10:00 – 10:30 Coffee break (*Sponsored by Amgen*)
- 10:30 – 11:00 Transforming operations with next generation Biomanufacturing  
Arleen Paulino, Amgen Singapore
- 11:00 – 11:30 Lifecycle approach to validation supports accelerated approvals  
Julia O'Neill, Tunnell Consulting
- 11:30 – 12:00 Continuous bioprocessing: Technology and regulatory challenges and mitigation strategies  
Mani Krishnan, Pall Lifesciences
- 12:00 – 13:00 Lunch
- 13:00 – 15:00 **Oral Session 5 – It's All About the Analytics**  
Chair: Mark Schenerman, Vice President, MedImmune
- 13:00 – 13:30 An FDA perspective on the implementation of state-of-the-art analytical methods for  
therapeutic proteins  
Marjorie Shapiro, FDA
- 13:30 – 14:00 Modernizing analytics for improved manufacturing efficiency – regulatory considerations  
Steven Rubin, FDA
- 14:00 – 14:30 Physicochemical assays and characterization  
Yang Wang, MedImmune
- 14:30 – 15:00 Bioassays and Effector Function  
Raju Shantha, MedImmune
- 15:00 – 15:30 Coffee break
- 15:30 – 17:30 **Workshops**  
Workshop 3 – It's all about the analytics  
(Chair: Mark Schenerman, MedImmune)  
Workshop 4 – Hot topics  
(Chair: Beth Junker, Bioprocess Advantage)
- 17:30 – 18:00 Coffee break

**Tuesday, April 25, 2017 (continued)**

- 18:00 – 19:00      **Keynote Lecture 3, Regulatory Sciences from a Regulator's, an Industrialist's and an Academic's Perspective**  
Robert Meyer, Virginia Center for Translational and Regulatory Sciences, University of Virginia
- 19:00 – 19:15      **Rapid Fire Oral Presentations/Poster Session Preview**  
Chair: Sevda Deldari, UMBC
- 19:15 – 20:30      Dinner
- 20:30 – 21:30      **Poster Session 2 / Social Hour**

**Wednesday, April 26, 2017**

- 07:30 – 08:30 Breakfast
- 08:30 – 09:30 **Keynote 4, Steven Kozlowski, FDA**
- 09:30 – 10:00 Coffee break
- 10:00 – 12:30 **Oral Session 6 – Risk-based characterization**  
Chairs: Thomas Ryll, Vice President, Immunogen and Jose Menezes, Professor, Instituto Superior Técnico, Portugal
- 10:00 – 10:30 Leveraging Mab cell culture platform to predict product quality  
Chris Kwiatkowski, Biogen
- 10:30 – 11:00 Comparability and similarity protocols for biotechnology products  
Francisca F. Gouveia, Pedro M. Felizardo, and José C. Menezes, 4Tune Engineering Ltd.
- 11:00 – 11:30 Pre-clinical to Phase III upstream process changes to support next generation manufacturing  
Sarwat Khattak, Biogen
- 11:30 – 12:00 Comparability assessment of an antibody-drug conjugate (ADC)  
Alex Lazar, ImmunoGen
- 12:00 – 12:30 Global implementation of a cell culture change: Strategies, lessons learned and challenges  
Marie-Pierre Gentile, Genentech
- 12:30 – 12:45 Closing Comments: Tony Moreira and David Robinson
- 12:45 – 1:45 Lunch and departures

## Poster Presentations

- 1. Influenza hemagglutinin glycoproteins with different N-glycan patterns activate dendritic cells in vitro**  
Suh-Chin Wu, Institute of Biotechnology, National Tsing Hua University, Taiwan
- 2. Rapid transient and stable protein production with consistent quality to accelerate biotherapeutic development**  
Weili Wang, MaxCyte, Inc., USA
- 3. Streamlining viral clearance strategy with generic claims and worst case studies**  
Brad Stanley, Biogen, USA
- 4. Utility of GMP Next Generation Sequencing (NGS) for biosafety assesment of biological products**  
Audrey Chang, BioReliance/MilliporeSigma, USA
- 5. Defining established conditions under ICH Q12 for Pre-QbD commercial products**  
Jose Menezes, 4Tune Engineering Ltd, Portugal
- 6. Critical considerations in bioreactor design to optimize cell-free protein expression in CHO**  
Chariz Johnstone, University of Maryland Baltimore County, USA
- 7. Reactivity and specificity of mice antisera generated from Coxsackievirus A6 and A10 vaccinations**  
Chia-Chyi Liu, National Health Research Institutes, Taiwan
- 8. Platform analytical methods approach “compendial-like” status**  
Carrie R. Lewis, MedImmune, USA
- 9. Development and validation of an IMAC purification platform for His-tagged proteins expressed in a CHO cell-free system**  
Sevda Deldari, University of Maryland Baltimore County, USA
- 10. Transferring methods for vaccine release between the industry, academy and a regulatory agency: Lessons learned**  
Elizabeth Carrasco, LAMMB, Instituto de Biotecnología, Mexico
- 11. Impact of a mutation in the podB gene on protein productivity in filamentous fungi**  
Karthik R. Boppidi, University of Maryland Baltimore County, USA
- 12. Fundamental studies of the mechanism of Ion exchange chromatography**  
Payam Rezaei, University of Maryland Baltimore County, USA
- 13. NIIMBL: The National Institute for Innovation in Manufacturing Biopharmaceuticals**  
Barry Buckland, BiologicB, USA
- 14. Expression and purification of highly complex therapeutics, tPA in a mammalian cell-free expression system**  
David Burgenson, University of Maryland Baltimore County, USA
- 15. Process development tools and initial results for the purification of therapeutic antibody products with neutral to acidic pI values using a non-affinity capture method**  
Yang Liu, University of Maryland Baltimore County, USA